2018, doi: 10.1007/s00296-018-4142-x Chourpiliadis, C., et al, "Use of Common Psychiatric Medications and Risk and Prognosis of Amyotrophic Lateral Sclerosis," JAMA Network Open, June 4, 2024, doi:10.1001/jamanetworkopen.2025.14437 Meron, M.K., et al, "GLP-1 receptor agonists and the risk of fragility fractures in older adults with type 2 diabetes," Journal of Clinical Endocrinology & Metabolism, Feb.10, 2026, doi: 10.1210/clinem/dgag056 Luo, Y., et al, "GLP-1 receptor agonists in eye disease: a comprehensive review of current research and future potential," BMC Ophthalmology, Jan
This hormone plays a vital role in telling your brain and body that youre full, regulating your appetite, and helping to manage your blood sugar
Possible adverse effects may include: Injection site reactions : Redness, swelling, irritation, or discomfort Gastrointestinal symptoms : Nausea, vomiting, stomach cramps, or diarrhea Headaches or dizziness Allergic reactions : Rash, itching, shortness of breath, or facial swelling (rare) Increased heart rate or anxiety (typically temporary from B-vitamins) Fatigue or weakness if used improperly Elevated liver enzymes when taken in excess particularly with methionine or choline Insomnia if taken late in the day due to increased energy levels Who should avoid or use caution
Rescheduling psilocybin and MDMA in Australia - A process explainer There is a proposal before Australia's poisons, medicines and drug regulator, the TGA (Therapeutic Goods Administration) to down-schedule MDMA and psilocybin from Schedule 9 to Schedule 8, for use in limited therapeutic settings
17(12): CR677CR682.
